Medicare Part B premiums are set to rise significantly in 2026 amid medical inflation, while Part D prescription drug costs slightly decline nationally. Enrollment opens October 15 for plan changes including Medicare Advantage and Medigap options.

Senator Peter Welch calls for bipartisan cooperation to extend ACA tax credits and prevent a government shutdown that threatens affordable healthcare for millions.

FDA approves prescription leucovorin for autism treatment; HHS addresses investment and regulatory concerns involving CMS administrator Dr. Mehmet Oz amid public discourse.

Rising healthcare inflation is leading to the largest health coverage cost increase for U.S. employers since 2010, driven by higher medical care prices and prescription drug expenses, especially GLP-1 drugs.

Explore Medicare coverage limitations for Saxenda, a GLP-1 agonist approved for weight loss, and the implications for obesity drug access and insurance plan strategies.

CMS's price-substitution policy has saved $76 million for Medicare by correcting drug pricing identified by the Office of Inspector General, improving cost efficiency while maintaining access.

CMS initiates survey collecting hospital outpatient drug acquisition costs to align Medicare payments with actual costs under the 2026 OPPS update, following a federal Executive Order to reduce prescription drug expenses.

Pennsylvania Senate passes Bill 95 with amendment requiring pharmacies to disclose retail and generic drug prices upon consumer request, promoting prescription drug cost transparency and informed purchasing decisions.

Explore the Medicare Part D coverage gap's impact on U.S. retirees, with insights on managing prescription drug costs and navigating supplemental insurance options.

U.S. federal agencies issue new guidance and requests for information to improve transparency in prescription drug and hospital prices, aiming to enhance data accuracy and compliance.